Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
For information on these and other studies, contact the Developmental Therapeutics team at recurrentcancer@stjude.org.
A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
For: Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma
A Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and of Natural Killer Cell Transplantation Versus Conventional Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
For: acute myeloid leukemia (AML)
Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia
For: Recurrent or refractory solid tumors and leukemias
A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) with and without Natural Killer Cells to Chemotherapy in Children and Adolescents with Recurrent/Refractory Neuroblastoma
For: Recurrent / refractory neuroblastoma
Pilot Study of Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
For: Acute lymphoblastic leukemia (ALL)
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF):A Phase IIB Randomized Placebo-Controlled Trial
For: congestive heart failure
A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children with Relapsed or Refractory Solid Tumors or Lymphomas
For: Relapsed or refractory solid tumors or lymphomas
A Pilot Pharmacokinetic, Pharmacodynamic, and Feasibility Study of Sorafenib in Combination with Cytarabine and Clofarabine in Patients with Refractory or Relapsed Hematologic Malignancies
For: Acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (both AML and ALL), AML w/prior myelodysplastic syndrome (MDS), myelodysplastic / myeloproliferative neoplasms, biphenotypic leukemia
A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma after Radical Resection
For: Craniopharyngioma
A Phase I trial of the humanized anti-GD2 antibody (hu12.18K322A) in children and adolescents with neuroblastoma, osteosarcoma and melanoma
For: Neuroblastoma, osteosarcoma and melanoma
Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants with Diffuse Intrinsic Pontine Glioma and High-Grade Glioma
For: Progressive or recurrent pontine glioma or high-grade glioma
Phase I Study of Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma
For: Newly diagnosed diffuse Intrinsic Pontine glioma and recurrent / progressive high grade glioma including diffuse intrinsic pontine glioma
A Phase I Study of 5-Fluorouracil In Children And Young Adults With Recurrent Ependymoma
For: Recurrent ependymoma
Non St. Jude Protocols
A Phase I dose escalation study of REOLYSIN, a replication competent reovirus, in pediatric patients with relapsed or refractory solid tumors
For: Recurrent solid tumors
A Phase I Study Of The C-Met Inhibitor Tivantinib (ARQ 197, IND#112603) In Children With Relapsed or Refractory Solid Tumors (ADVL1111)
For: Relapsed or refractory solid tumors or brain tumors
A Phase I Study of AMG 386 (IND#114215), An Angiopoietin Neutralizing Peptibody, In Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors (ADVL1115)
For: Relapsed or refractory solid tumors, including CNS tumors
A Phase I Study of XL184 (Cabozantinib, IND# 116059) In Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors (ADVL1211)
For: Recurrent or refractory solid tumors, including CNS tumors
A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-Met, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma
For: Relapses/refractory solid tumors and anaplastic large cell lymphoma
A Phase II Study of MLN8237 (IND#102984), A Selective Aurora Kinase Inhibitor, In Children with Recurrent/Refractory Solid Tumors and Leukemias (ADVL0921)
For: recurrent or refractory solid tumors (including rhabdoid and malignant germ cell tumors of the CNS) and leukemias
A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
For: Relapsed or refractory B-precursor acute lymphoblastic leukemia
A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Tumor (SCUSF 0901; ACCL0922) Site CTEP ID= TN024
For: Previously treated brain tumors
A phase I, multi-center, dose escalation study of CAT-8015 in children, adolescents and young adults with refractory CD22+ acute lymphoblastic leukemia (ALL), or non-Hodgkin’s Lymphoma (NHL) (CAT-8015-1004)
For: acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), including lymphoblastic lymphoma, Burkitt’s lymphoma, and large cell lymphoma
A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients - A Children’s Oncology Group (COG) Study (ACNS1021)
For: Recurrent, refractory or progressive glioma and ependymoma
A Phase II Randomized Trial of Lenalidomide (NSC#703813, IND#70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas
For: Recurrent, refractory or progressive brain tumors
Phase II Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors
For: Newly diagnosed localize primary NGGCT or newly diagnosed localized germinoma
Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
For: Diffuse intrinsic pontine gliomas
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL (TACL protocol T2009-003)
For: Relapsed ALL
A Phase 2 Study of Ipilimumab in Children and adolescents (12 to < 18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
For: Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma
An Open-label, Multicenter, Single-arm, Phase I Dose-escalation with Efficacy Tail Extension study of R05185426 in Pediatric Patients with Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600
For: melanoma
A Phase I Pediatric Study of a Plerixafor Containing Regimen in Second Allogeneic Stem Cell Transplantation
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide) in T-ALL Relapse: A Joint Study of TACL and POETIC
For: Leukemia
Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents
For: Human Immunodeficiency Virus
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
For: Relapsed acute lymphoblastic leukemia [ALL], acute myelogenous leukemia [AML], Hodgkin disease [HD] and non-Hodgkin’s lymphomas [NHL]
Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma/ Brain Tumor
For: Gliomas
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma
For: Recurrent or refractory medulloblastoma
A Phase I /II Study of ABT-888, an Oral Poly (ADP-Ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, followed by ABT-888 and Temozolomide (TMZ), in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
For: newly diagnosed diffuse intrinsic pontine gliomas (DIPG)
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil furamate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naïve Adolescents
For: HIV infections
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung
For: recurrent osteosarcoma
